CASIA OpenIR  > 脑图谱与类脑智能实验室  > 脑网络组研究
A Pathway-Specific Polygenic Risk Score Is Associated with Tau Pathology and Cognitive Decline
Sun, Yuqing1,2,3; Wang, Meng1,2,3; Zhao, Yuxin1,2,3; Hu, Ke1,2,3; Liu, Yong4; Liu, Bing5,6
发表期刊JOURNAL OF ALZHEIMERS DISEASE
ISSN1387-2877
2022
卷号85期号:4页码:1745-1754
摘要

Background: Tauopathy is a primary neuropathological hallmark of Alzheimer's disease with a strong relationship to cognitive impairment. In the brain, tau aggregation is associated with the regulation of tau kinases and the binding ability of tau to microtubules. Objective: To explore the potential for using specific polygenic risk scores (PRSs), combining the genetic influences involved in tau-protein kinases and the tau-protein binding pathway, as predictors of tau pathology and cognitive decline in non-demented individuals. Methods: We computed a pathway-specific PRS using summary statistics from previous large-scale genome-wide association studies of dementia. We examined whether PRS is related to tau uptake in positron emission tomography (PET), tau levels, and the rate of tau level changes in cerebrospinal fluid (CSF). We further assessed whether PRS is associated with memory impairment mediated by CSF tau levels. Results: A higher PRS was related to elevated CSF tau levels and tau-PET uptake at baseline, as well as greater rates of change in CSF tau levels. Moreover, PRS was associated with memory impairment, mediated by increased CSF tau levels. The association between PRS and tau pathology was significant when APOE was excluded, even among females. However, the effect of PRS on cognitive decline appeared to be driven by the inclusion of APOE. Conclusion: The influence of genetic risk in a specific tau-related biological pathway may make an individual more susceptible to tau pathology, resulting in cognitive dysfunction in an early preclinical phase of the disease.

关键词Alzheimer's disease cognitive function genetic risk scores pathway tau
DOI10.3233/JAD-215163
关键词[WOS]ALZHEIMERS-DISEASE ; CEREBROSPINAL-FLUID ; NEUROFIBRILLARY TANGLES ; BIOMARKERS ; PHOSPHORYLATION ; PROTEIN ; ONSET ; AGE
收录类别SCI
语种英语
资助项目National Natural Science Foundation of China[81771451] ; National Natural Science Foundation of China[81871438] ; Beijing Natural Science Funds for Distinguished Young Scholar[JQ20036] ; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)[U01AG024904] ; DOD ADNI (Department of Defense)[W81XWH-12-2-0012] ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; Alzheimer's Association ; Alzheimer's Drug Discovery Foundation ; Araclon Biotech ; Biogen ; CereSpir, Inc. ; Cogstate ; Elan Pharmaceuticals, Inc. ; Eli Lilly and Company ; EuroImmun ; F. Hoffmann-La Roche Ltd, ; Genentech, Inc. ; Fujirebio ; GE Healthcare ; IXICO Ltd. ; Janssen Alzheimer Immunotherapy Research & Development, LLC. ; Johnson & Johnson Pharmaceutical Research & Development LLC. ; Lumosity ; Lundbeck ; Merck Co., Inc. ; Meso Scale Diagnostics, LLC. ; NeuroRx Research ; Neurotrack Technologies ; Novartis Pharmaceuticals Corporation ; Pfizer Inc. ; Piramal Imaging ; Servier ; Takeda Pharmaceutical Company ; Transition Therapeutics ; Canadian Institutes of Health Research ; AbbVie ; Bristol-Myers Squibb Company ; Eisai Inc.
项目资助者National Natural Science Foundation of China ; Beijing Natural Science Funds for Distinguished Young Scholar ; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) ; DOD ADNI (Department of Defense) ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; Alzheimer's Association ; Alzheimer's Drug Discovery Foundation ; Araclon Biotech ; Biogen ; CereSpir, Inc. ; Cogstate ; Elan Pharmaceuticals, Inc. ; Eli Lilly and Company ; EuroImmun ; F. Hoffmann-La Roche Ltd, ; Genentech, Inc. ; Fujirebio ; GE Healthcare ; IXICO Ltd. ; Janssen Alzheimer Immunotherapy Research & Development, LLC. ; Johnson & Johnson Pharmaceutical Research & Development LLC. ; Lumosity ; Lundbeck ; Merck Co., Inc. ; Meso Scale Diagnostics, LLC. ; NeuroRx Research ; Neurotrack Technologies ; Novartis Pharmaceuticals Corporation ; Pfizer Inc. ; Piramal Imaging ; Servier ; Takeda Pharmaceutical Company ; Transition Therapeutics ; Canadian Institutes of Health Research ; AbbVie ; Bristol-Myers Squibb Company ; Eisai Inc.
WOS研究方向Neurosciences & Neurology
WOS类目Neurosciences
WOS记录号WOS:000759157200028
出版者IOS PRESS
七大方向——子方向分类医学影像处理与分析
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.ia.ac.cn/handle/173211/48067
专题脑图谱与类脑智能实验室_脑网络组研究
通讯作者Liu, Yong; Liu, Bing
作者单位1.Univ Chinese Acad Sci, Sch Artificial Intelligence, Beijing, Peoples R China
2.Chinese Acad Sci, Brainnetome Ctr, Inst Automat, Beijing, Peoples R China
3.Chinese Acad Sci, Natl Lab Pattern Recognit, Inst Automat, Beijing, Peoples R China
4.Beijing Univ Posts & Telecommun, Sch Artificial Intelligence, Beijing 100876, Peoples R China
5.Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing 100875, Peoples R China
6.Chinese Inst Brain Res, Beijing, Peoples R China
第一作者单位模式识别国家重点实验室
推荐引用方式
GB/T 7714
Sun, Yuqing,Wang, Meng,Zhao, Yuxin,et al. A Pathway-Specific Polygenic Risk Score Is Associated with Tau Pathology and Cognitive Decline[J]. JOURNAL OF ALZHEIMERS DISEASE,2022,85(4):1745-1754.
APA Sun, Yuqing,Wang, Meng,Zhao, Yuxin,Hu, Ke,Liu, Yong,&Liu, Bing.(2022).A Pathway-Specific Polygenic Risk Score Is Associated with Tau Pathology and Cognitive Decline.JOURNAL OF ALZHEIMERS DISEASE,85(4),1745-1754.
MLA Sun, Yuqing,et al."A Pathway-Specific Polygenic Risk Score Is Associated with Tau Pathology and Cognitive Decline".JOURNAL OF ALZHEIMERS DISEASE 85.4(2022):1745-1754.
条目包含的文件 下载所有文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
JAD215163.pdf(695KB)期刊论文作者接受稿开放获取CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sun, Yuqing]的文章
[Wang, Meng]的文章
[Zhao, Yuxin]的文章
百度学术
百度学术中相似的文章
[Sun, Yuqing]的文章
[Wang, Meng]的文章
[Zhao, Yuxin]的文章
必应学术
必应学术中相似的文章
[Sun, Yuqing]的文章
[Wang, Meng]的文章
[Zhao, Yuxin]的文章
相关权益政策
暂无数据
收藏/分享
文件名: JAD215163.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。